NCT07400315尚未招募2 期
A Prospective, Single-arm, Multicenter, Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Modified FLOT Regimen (TFOX) as First-line Treatment for HER2-negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 64
- 主要终点
- Median progression-free survival
研究概览
简要总结
A prospective, single-arm, multicenter, Phase II clinical study of Apatolimab Tovolimab (QL1706) in combination with modified FLOT regimen (TFOX) as first-line treatment for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1. The participant voluntarily agrees to participate in this study, signs the informed consent form, and strictly adheres to the requirements of the study protocol.
- •2. Age ≥18 years and ≤75 years at enrollment, regardless of gender.
- •3. Histologically confirmed unresectable locally advanced or metastatic G/GEJ adenocarcinoma, with inclusion criteria specifying HER2- status (HER2+ status defined as IHC3+ or IHC2+ and FISH+).
- •4. No prior systemic treatment for unresectable locally advanced or metastatic G/GEJ adenocarcinoma; previous neoadjuvant and/or adjuvant therapy is acceptable, but all systemic treatments must have been completed at least 12 months prior to the diagnosis of unresectable or metastatic disease.
- •5. At least one measurable tumor lesion according to RECIST 1.1 criteria.
- •6. ECOG PS of 0 or
- •7. Life expectancy ≥3 months.
- •8. Fully recovered from any toxicities related to prior treatments prior to enrollment in the study.
- •9. BMI >
- •10. Adequate function of major organs
- •11. Fertile subjects must use appropriate contraception during the study and for 120 days after the end of the study. They must have a negative serum pregnancy test within 7 days prior to enrollment and must not be breastfeeding.
排除标准
- •1. Any unstable systemic disease: including active infection, uncontrolled hypertension, unstable angina, angina that started within the last 3 months, congestive heart failure (New York Heart Association [NYHA] ≥Class II), myocardial infarction within 6 months prior to enrollment, severe arrhythmias requiring medication, or hepatic, renal, or metabolic diseases.
- •2. Symptomatic brain and/or leptomeningeal metastases.
- •3. Known deficiency of dihydropyrimidine dehydrogenase (DPD).
- •4. QT/QTc interval >450 ms for males, >470 ms for females.
- •5. History of other malignancies within 5 years prior to enrollment, with the exception of adequately treated cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma of the skin.
- •6. History of organ transplantation or autologous/allogeneic stem cell transplantation.
- •7. Currently receiving systemic immunotherapy or hormone therapy other than physiologic replacement therapy.
- •8. Other concurrent anti-tumor treatments.
- •9. Known hypersensitivity or allergic reaction to any component of the study treatment.
- •10. Previous exposure to docetaxel or oxaliplatin (except for adjuvant chemotherapy).
- •11. Previous exposure to immune checkpoint inhibitors (e.g., anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-CTLA-4 antibodies), immune checkpoint agonists (e.g., antibodies targeting ICOS, CD40, CD137, GITR, OX40), or any immunotherapy targeting tumor immune mechanisms.
- •12. Participants with severe bone marrow failure.
- •13. Any disease, metabolic disorder, or physical examination or laboratory findings that suggest contraindications to the study drug or high-risk factors for treatment complications.
- •14. Known or self-reported human immunodeficiency virus (HIV) infection.
- •15. Participants who are HBV or HCV positive.
- •16. Pregnant or breastfeeding.
- •17. Received a live vaccine within 4 weeks prior to the first dose, or plans to receive a live vaccine during the study.
- •18. Participated in any investigational drug treatment or used any investigational device within 4 weeks prior to the first dose.
- •19. Any condition that the investigator believes may pose a risk to the participant receiving the study drug, or may interfere with the evaluation of the study drug, the safety of the participant, or the interpretation of the study results.
研究组 & 干预措施
Experimental
Experimental
干预措施: Iparomlimab and Tuvonralimab Injection in combination with TFOX (Drug)
结局指标
主要结局
Median progression-free survival
时间窗: 1 year
次要结局
- Objective response rate ,ORR(1 year)
- Disease Control Rate(1 year)
- Duration Of Response(1 year)
- Overall survival ,OS(up to 5 years after treatment discontinuation)
- 12-month survival rate(12-month)
- 24-month survival rate(24-month)
- Number of participants with treatment-related adverse events as assessed by CTCAE v5.0(From ICF through 100 days after the last dose of study treatment)
研究者
相似试验
招募中
2 期
QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTTNCT07327788Nanfang Hospital, Southern Medical University38
招募中
2 期
Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal CarcinomaNCT07362979Sun Yat-sen University243
招募中
1 期
Atamparib in Patients With Advanced Solid TumorsNCT07374419Nerviano Medical Sciences (Shanghai) Ltd.178
尚未招募
3 期
Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical TrialEsophageal CancerNCT07332221Henan Cancer Hospital435
招募中
2 期
Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction CancerNCT07315854Beijing Friendship Hospital32